Boston Scientific Corporation vs NRG Energy Inc — how do they compare? Boston Scientific Corporation trades at $43.3 (market cap $66.37B), while NRG Energy Inc trades at $137.93 (market cap $29.19B). The key difference: Boston Scientific Corporation is far larger — about 2.3× NRG Energy Inc's market cap, and NRG Energy Inc pays a 1.37% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | NRG | |
|---|---|---|
Market Cap | $66.37B | $29.19B |
Sector | Health | Utilities |
52-Week High | $108.14 | $184.03 |
52-Week Low | $42.63 | $120.65 |
Enterprise Value | $75.94B | $53.02B |
Dividend Yield | — | 1.37% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
NRG Energy trades at $139.48, down 0.67% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 153.27 but attractive P/S of 0.86, while revenue grew to $30.71B in 2025. Analyst sentiment remains positive with 64% buy ratings, though technical indicators suggest near-term pressure with support at $138.
Outlook is cautiously optimistic given strong analyst support and dividend payments, but risks include high debt levels and volatile cash flows. Investors should weigh solid revenue growth against margin compression and elevated valuation multiples before positioning.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →